We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Cytiva has finalized a $31 million deal with HHS’ Biomedical Advanced Research and Development Authority to develop and manufacture COVID-19 vaccine component parts. Read More
In evaluations of its test, Abbott found that it provided 99.56 percent specificity and 95 percent sensitivity for patients tested 15 days after symptom onset. Read More
The first participant has been dosed in Vaxart’s phase 1 study of an oral COVID-19 vaccine tablet the company is developing as an alternative to injectable vaccines. If approved, it would be the first-ever vaccine in tablet form. Read More
A clinical trial of Eli Lilly’s antibody candidate treatment for COVID-19 was paused Tuesday following a safety incident — awkward timing as the company has just applied to the FDA for an Emergency Use Authorization (EUA) for the product. Read More
Novavax said it will look into developing a combined influenza/COVID-19 vaccine for post-pandemic use that would unite two of its vaccine candidates. Read More